| Santhera Pharmaceuticals (Schweiz) AG - Agamree 40 mg/ml, Suspension zum Einnehmen | | 69650 | | 01 | | Agamree 40 mg/ml | | Suspension zum Einnehmen | | H02AB18 | | Vamorolone | | 14.01.2026 | | |
| | Composition | | vamorolonum 40 mg, sucralosum, xanthani gummi, dinatrii phosphas, acidum citricum monohydricum, E 211 1 mg, glycerolum 50 mg, aromatica (Orange), acidum hydrochloridum, aqua purificata ad suspensionem pro 1 ml corresp. natrium 1.064 mg. | | Packungsbestandteile | | Suspension (orale) | | | | | | Principe actif | Concentr. |
|---|
| Vamorolonum | 40 mg/ml |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| Acide Citrique Monohydre | | | | Acidum Hydrochloridum | | | | Aromatica (Orange) | | | | Disodium Phosphate | | | | E 211 | 1 mg/ml | conserv. | | Glycerol | 50 mg/ml | | | Sucralosum | | | | Xanthani Gummi | | |
|
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 001 | 100 ml | | | A | | Oui |
|
|
